[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336480-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336480-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","clinical-trial-protocol-for-rosella-a-phase-3-study-of-relacorilant-in-combination-with-nab-paclitaxel-versus-nab-paclitaxel-monotherapy-in-advanced-platinum-resistant-ovarian-cancer","Clinical Trial Protocol for ROSELLA - a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer","","Clinical trial protocol for ROSELLA addresses unmet needs in advanced platinum-resistant ovarian cancer, highlighting high mortality driven by late diagnosis and development of chemoresistance in recurrent disease. The study evaluates relacorilant combined with nab-paclitaxel versus nab-paclitaxel monotherapy, aiming to improve clinical outcomes for women with platinum-resistant disease. Publication details include received and accepted dates and online publication timing.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinical-trial-protocol-for-rosella-a-phase-3-study-of-relacorilant-in-combination-with-nab-paclitaxel-versus-nab-paclitaxel-monotherapy-in-advanced-platinum-resistant-ovarian-cancer/336480/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinical-trial-protocol-for-rosella-a-phase-3-study-of-relacorilant-in-combination-with-nab-paclitaxel-versus-nab-paclitaxel-monotherapy-in-advanced-platinum-resistant-ovarian-cancer/336480.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical problem does the ROSELLA protocol target?","Question",{"text":63,"@type":64},"ROSELLA targets the poor outcomes in advanced platinum-resistant ovarian cancer, driven by late-stage diagnosis and chemoresistance in recurrent disease.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What treatment strategies are compared in this phase 3 study?",{"text":68,"@type":64},"The protocol compares relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is improving outcomes considered a substantial unmet need?",{"text":72,"@type":64},"The document links unmet need to the high mortality of ovarian cancer and the development of chemoresistance in recurrent disease, which limits effective options.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336480,1790297712,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","J Gynecol Oncol. 2024 Jul;35(4):e111 [https://doi.org/10.3802/jgo.2024.35.e111](https://doi.org/10.3802/jgo.2024.35.e111)[ ](https://doi.org/10.3802/jgo.2024.35.e111)pISSN 2005-0380·eISSN 2005-0399  \nClinical Trial Protocol  \nReceived: May 28, 2024  \nAccepted: Jun 11, 2024  \nPublished online: Jun 26, 2024  \nCorrespondence to  \nAlexander B. Olawaiye  \nUniversity of Pittsburgh School of Medicine and Magee-Womens Hospital, Magee-Women’s Hospital, Gynecologic Oncology Group, 300 Halket St., Pittsburgh, PA 15213, USA. [Email: olawaiyea@upmc.edu](Email: olawaiyea@upmc.edu)  \n*Current affiliation: Humanitas University, Rozzano (MI) and Humanitas San Pio X, Milan, Italy.  \n© 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nAlexander B. Olawaiye  [https://orcid.org/0000-0002-2833-9255](https://orcid.org/0000-0002-2833-9255)[ ](https://orcid.org/0000-0002-2833-9255)Jae-Weon Kim  [https://orcid.org/0000-0003-1835-9436](https://orcid.org/0000-0003-1835-9436)[ ](https://orcid.org/0000-0003-1835-9436)Andrea Bagameri  [https://orcid.org/0009-0007-5519-2598](https://orcid.org/0009-0007-5519-2598)[ ](https://orcid.org/0009-0007-5519-2598)Erin Bishop  [https://orcid.org/0000-0002-9914-4754](https://orcid.org/0000-0002-9914-4754)[ ](https://orcid.org/0000-0002-9914-4754)Anita Chudecka-Głaz  [https://orcid.org/0000-0003-2784-7968](https://orcid.org/0000-0003-2784-7968)  \nClinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer  \nAlexander B. Olawaiye ,1 Jae-Weon Kim ,2 Andrea Bagameri ,3 Erin Bishop ,4 Anita Chudecka-Głaz ,5 Alix Devaux ,6 Laurence Gladieff ,7 Mary E. Gordinier ,8 Jacob Korach ,9 Michael E. McCollum ,10 Linda Mileshkin ,11 Bradley J. Monk ,12 Shibani Nicum ,13 Angélica Nogueira-Rodrigues ,14 Ana Oaknin ,15  \nDavid M. O’Malley ,16 Mauro Orlando ,17 Lyndah Dreiling ,18 Iulia C. Tudor ,18 Domenica Lorusso  19,*  \n1University of Pittsburgh School of Medicine and Magee-Womens Hospital, Gynecologic Oncology Group, Pittsburgh, PA, USA  \n2Department of Obstetrics and Gynecology, Seoul National University, Seoul, Korea  \n3National Institute of Oncology, Budapest, Hungary  \n4Medical College of Wisconsin, Gynecologic Oncology Group, Milwaukee, WI, USA  \n5Pomeranian Medical University, Polish Gynecologic Oncology Group, Szczecin, Poland  \n6Oncology Department of Grand Hôpital de Charleroi, Charleroi, Belgium  \n7Institut Claudius Regaud-Institut Universitaire du Cancer de Toulouse Oncopole, Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens, Toulouse, France  \n8Norton Cancer Institute, Louisville, KY, USA  \n9Sheba Medical Center, School of Medicine, Tel Aviv University, Israeli Society of Gynecologic Oncology, Tel Aviv, Israel  \n10Virginia Oncology Associates, Norfolk, VA, USA  \n11Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia  \n12Gynecologic Oncology Group Foundation; Florida Cancer Specialists and Research Institute, West Palm Beach, FL, USA  \n13University College London Cancer Institute, National Cancer Research Institute, London, UK  \n14Federal University of Minas Gerais, Dom Oncologia and Oncoclinicas-Brazil, Belo Horizonte, Brazil 15Medical Oncology Service, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain  \n16The Ohio State University and the James Cancer Center, Gynecologic Oncology Group, Columbus, OH, USA  \n17Instituto Alexander Fleming, Buenos Aires","cbCaieJuFCwkE9TF","https://ap.wps.com/l/cbCaieJuFCwkE9TF","pdf",2073799,"English","# Background\n## Rationale for improved outcomes in platinum-resistant ovarian cancer\n# Study Design Overview\n## Comparison of relacorilant plus nab-paclitaxel vs nab-paclitaxel monotherapy\n# Publication Information\n## Received, accepted, published online details\n# Correspondence and Affiliations\n## Corresponding author and author affiliations","[{\"question\":\"What clinical problem does the ROSELLA protocol target?\",\"answer\":\"ROSELLA targets the poor outcomes in advanced platinum-resistant ovarian cancer, driven by late-stage diagnosis and chemoresistance in recurrent disease.\"},{\"question\":\"What treatment strategies are compared in this phase 3 study?\",\"answer\":\"The protocol compares relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy.\"},{\"question\":\"Why is improving outcomes considered a substantial unmet need?\",\"answer\":\"The document links unmet need to the high mortality of ovarian cancer and the development of chemoresistance in recurrent disease, which limits effective options.\"}]","Clinical Trial Protocol for ROSELLA - a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer | PDF",1790015271,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb0d77f2e596bcd86871f6cfb552c117.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a37c4febf728f7cc298457ddc09733ec.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17d036151f98b18ee0f15ac5f6dd52ca.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f75abc73410ed481657801837dcff1eb.webp",980,1306]